Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
dHACM is a section of tissue made from part of the placenta donated by a mother during a C-section. It looks like a small piece of tissue paper and is wrapped around the nerve bundles in the surgical area. The tissue may help the body's normal healing process.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If participant is eligible and agrees to take part in the study, they will be randomly assigned (as in the flip of a coin) to 1 of 2 groups. Participant will have an equal chance of being in either group. This is done because no one knows if one study group is better, the same, or worse than the other group:
* If participant is in Group 1, they will have RARP with dHACM.
* If participant is in Group 2, they will have RARP alone.
Participant will not be told which group they are assigned to until they reach the end of the study. Participant will sign a separate consent form for the surgery that explains the risks.
During Surgery:
If participant is in Group 1, the dHACM will be wrapped around the nerve bundles at the end of the surgery.
For both groups, during the surgery, participant's surgeon may decide that RARP is not possible. In this case, participant will be taken off the study and dHACM will not be used.
Information will also be collected during participant's surgery, such as details about their surgery, their hospital stay, and about any side effects that they may have.
Study Visits:
Participant will visit the study doctor for their standard follow-up visits after surgery at 6 weeks, 3 months, 6 months, and 12 months. At these visits, participant will complete the same questionnaire they completed at screening.
At 24 months, participant's medical chart will be reviewed or they will be called on the phone to learn if the disease came back. If participant is called, the call should last about 5-10 minutes.
Length of Study Participation:
Patient's participation in the study will be over after the 24-month medical chart review or call.
This is an investigational study. The dHACM is commercially available for use in various types of surgeries. Its use in prostate surgery to help improve the return of erectile function and bladder control in patients after RARP is investigational.
Up to 100 participants will be enrolled in this study. All will take part at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nerve Sparing RARP + AmnioFix®
Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) plus placement of a 2x12 sheet of AmnioFix® to the neurovascular bundle.
Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)
Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
AmnioFix®
Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
Questionnaire
Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
Nerve Sparing RARP
Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP)
Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)
Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
Questionnaire
Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)
Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
AmnioFix®
Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
Questionnaire
Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Primary diagnosis of prostate cancer selected for surgical intervention by one of the six protocol surgeons (Chapin, Davis, Matin, Pettaway, Pisters, Ward).
3. Have a willingness to comply with follow-up HRQOL (health related quality of life) surveys and PSA assessments.
4. Have ability to provide full written consent.
5. Primary diagnosis of untreated with clinically localized prostate cancer with Gleason score of 6, 7,8 or 9.
6. Planned elective radical prostatectomy with bilateral nerve sparing technique that can include high or low fascia.
7. Negative urinalysis within 30 days prior to date of surgery
Exclusion Criteria
2. Has any condition(s), which seriously compromises the subject's ability to participate in this study, sign consent, or has a known history of poor adherence with medical treatment.
3. Is unable to comply with learning and documenting penile rehabilitation, including oral 5-phosphodiesterase inhibitor use, vacuum pump therapy use, and/or injectable medications.
4. In the opinion of the PI, has a history of drug or alcohol abuse within last 12 months.
5. Is allergic to Aminoglycoside antibiotics (such as Gentamicin and/or Streptomycin).
6. Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
7. Patients currently enrolled in another study. Concurrent enrollment in another study is prohibited expect for the control arm which can be used for other protocols with HRQOL endpoints with similar instruments.
8. Has had prior hormonal therapy such as Lupron or oral anti-androgens.
9. Unwilling to participate in follow-up clinical appointments at MDACC.
35 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MiMedx Group, Inc.
INDUSTRY
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John W. Davis, MD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2016-00342
Identifier Type: REGISTRY
Identifier Source: secondary_id
2015-0633
Identifier Type: -
Identifier Source: org_study_id